Renovia develops first-line digital therapeutic and diagnostic devices for women with pelvic floor disorders. Its technology combines proprietary sensor hardware and form factors with patient-facing apps and data management to visualize pelvic movement in real time and monitor usage and progress. The company has an existing FDA-cleared device that targets the levator plate to isolate and direct optimal pelvic-floor movement. Renovia’s pipeline includes additional digital therapeutic and diagnostic products intended to improve diagnosis and treatment of conditions such as urinary incontinence. The company plans to use financing to support clinical trials, product development, corporate development and future commercial launches. Since its founding in 2016, Renovia has positioned itself to deliver scalable, cost-effective digital health solutions aimed at lowering long-term healthcare costs for pelvic floor disorders.

Total raised

$42M

Funding rounds

2

Latest round

Series B

Latest activity

Aug 2018